Edwards Lifesciences (EW) Announces Strong SAPIEN 3 TAVR Data vs. Surgery
- Wall Street rallies, weekly losing streak continues
- Twitter (TWTR) Stock Collapses 20% as Musk Says $44 Billion Deal is 'Temporarily On Hold', Tesla (TSLA) Shares Rally
- Sam Bankman-Fried, Emergent Fidelity Amass 7.6% Stake in Robinhood (HOOD)
- Oil jumps 4% as U.S. gasoline prices hit record high
- 'Exodus From Wall Street', 'Crypto Implosion': BofA's Hartnett Says Crypto and Speculative Tech Collapse Now Rivals Dot-com Bubble Crash and GFC
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Edwards Lifesciences Corporation (NYSE: EW) announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke. The results of the study of 1,078 enrolled patients with severe, symptomatic aortic stenosis were presented as part of the late-breaking clinical trials at the American College of Cardiology's 65th Annual Scientific Session (ACC.16) in Chicago, and simultaneously published online in The Lancet.
"Results from the PARTNER II Trial presented at ACC should establish the SAPIEN 3 valve as the new benchmark for the treatment of intermediate-risk patients with severe, symptomatic aortic stenosis," said Vinod Thourani, M.D., co-director, Structural Heart and Valve Center of the Emory Heart and Vascular Center, chief of cardiothoracic surgery at Emory Hospital Midtown and professor of surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine. Thourani is the co-principal investigator of the SAPIEN 3 study. "The size and rigor of this 3,000-patient PARTNER II Trial provide powerful evidence in favor of this therapy for the treatment of patients with aortic stenosis."
From February 2014 through September 2014, 1,078 intermediate-risk patients were enrolled in the SAPIEN 3 study at 51 sites in the United States and Canada. One-year SAPIEN 3 outcomes were compared with one-year surgical outcomes from 944 intermediate-risk patients treated with surgery in the PARTNER II randomized trial. Important clinical measures from the study are presented in the table below.
Clinical Outcomes from The PARTNER II Intermediate-Risk Trial with the SAPIEN 3 Valve (As-Treated)*:
Clinical Outcomes (As-Treated)
SAPIEN 3 (N = 1,077)
Surgery (N = 944)**
SAPIEN 3 (N = 1,077)
Surgery (N = 944)**
Death: all-cause - %
Death: cardiovascular - %
Stroke: all - %
Stroke: disabling - %
All-cause Death and Disabling Stroke
*In a pre-specified propensity-score analysis developed in partnership with the FDA, outcomes from the SAPIEN 3 TAVR patient cohort were compared with outcomes from the surgical arm of the PARTNER II A Trial.** The full PARTNER II Trial two-year results of intermediate-risk patients were presented at ACC on April 2, and published online in The New England Journal of Medicine.
Moderate or severe aortic regurgitation was 0.6 percent for surgery which was superior to the 1.5 percent for TAVR at one year.
The SAPIEN 3 valve was approved by the U.S. Food and Drug Administration in June 2015 for the treatment of high-risk patients with severe, symptomatic aortic stenosis; the valve is not approved for the treatment of intermediate-risk patients in the U.S. The company has been planning for a U.S. approval late this year. More information on financial guidance and timing will be available during the company's earnings call April 26. The SAPIEN family of valves has been used in the treatment of more than 150,000 patients globally.
Edwards is conducting an investor event Sunday, April 3, 2016, at 6:30 p.m. Eastern/5:30 p.m. Central. This event will be accessible via live webcast at http://ir.edwards.com and available for replay on the "Investor Relations" section of the Edwards web site.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Blockchain (APLD) Reports Q3 Adjusted EPS of ($0.04)
- Vulcan Materials (VMC) Issues Update on Mexico Operations
- Micron (MU) Stock is a 'Steal', Says Analyst After Attending Investor Day
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Management Comments
Related EntitiesTwitter, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!